Project Grant R01CA301574
Award Date 3/24/26
Completion Date 2/28/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Summary Dana-Farber Cancer Institute, Inc. received a $855,249 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded September 1, 2025, with a completion date of August 1, 2032. The award supports research into new approaches for targeting cell cycle proteins, specifically cyclin-dependent kinases (CDKs), as a strategy for cancer treatment. The research addresses current limitations in CDK inhibitor therapy,...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $581,381 to Sloan-Kettering Institute for Cancer Research on June 5, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate the role of microhomology-mediated end-joining (MMEJ) in DNA damage repair and its implications for cancer drug resistance. The five-year research initiative (concluding May 31, 2030) will produce scientific research and experimental findings...
- Federal Grant Award Summary The National Cancer Institute awarded $125,619 to the Stowers Institute for Medical Research under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2030. This Project Grant supports research into centromere biology and chromosome segregation mechanisms that contribute to genomic instability—a hallmark of cancer development. The primary deliverables include experimental research characterizing how natural...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $151,040 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on December 23, 2025, with an ultimate completion date of September 14, 2027. This award supports postdoctoral research training and career development focused on dissecting the structural mechanisms of oligomeric BAK (BAKO) protein and its implications for reactivating apoptosis in cancer cells....
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Sloan-Kettering Institute for Cancer Research a $3.2 million Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning August 1, 2025, and concluding July 31, 2029. This research initiative investigates the mechanisms of extrachromosomal DNA (ecDNA) segregation and repair in cancer cells, with emphasis on understanding how ecDNA's circular topology contributes to tumor progression...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $241,884 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on September 3, 2025, with a completion date of August 31, 2030. This five-year research training and development award supports Dr. Cynthia Hahn's cancer immunology research focused on understanding immune evasion mechanisms in diffuse large B-cell lymphoma (DLBCL) through HLA-E (human...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $339,736 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to Dana-Farber Cancer Institute, Inc. (DFCI) on May 7, 2025, with completion anticipated by April 30, 2030. This award supports research aimed at resolving diagnostic and phenotypic challenges in translocation renal cell carcinoma (TRCC), a rare and aggressive cancer subtype that is frequently misdiagnosed due to phenotypic overlap with...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Harvard Medical School, effective March 13, 2026 through February 28, 2029. This award supports the development of high-throughput technological tools designed to track the fate of prematurely terminated transcripts in cancer cells. Specifically, the research focuses on alternative polyadenylation (APA) events—post-transcriptional gene...